Literature DB >> 15816542

Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines.

Bruno Buecher1, Delphine Bouancheau, Alexis Broquet, Stéphane Bezieau, Marc G Denis, Christian Bonnet, Marie-Françoise Heymann, Anne Jarry, Jean-Paul Galmiche, Hervé M Blottière.   

Abstract

BACKGROUND: Epidemiological studies have revealed a protective effect of NSAIDs, which principally target cyclooxygenase (COX)-1 and COX-2, on the development of colorectal cancer. Increased expression of COX-2 was shown in colorectal adenocarcinoma. However, some effects were shown to be COX-independent. Here, we compared two selective COX-2 inhibitors for their effect on the growth of colorectal tumour cells in vitro.
MATERIALS AND METHODS: Fifteen tumour cell lines were characterized for COX-1 and COX-2 expression by Western blot and RT-PCR. The effect of celecoxib and rofecoxib on their growth was assessed by staining of DNA with crystal violet.
RESULTS: COX-2 expression varied among cell lines, whereas COX-1 was always expressed. Rofecoxib displayed a limited dose-related effect on cell proliferation, whereas celecoxib strongly inhibited cell growth at high concentrations. Both effects appeared COX-2-independent.
CONCLUSION: Rofecoxib, which is devoid of apoptotic effect at high concentration but efficient at pharmacological concentrations, revealed a potential new mechanism of action of NSAIDs towards colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816542

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Lactobacillus rhamnosus GG increases cyclooxygenase-2 expression and prostaglandin E2 secretion in colonic myofibroblasts via a MyD88-dependent mechanism during homeostasis.

Authors:  Gabriela Uribe; Romain Villéger; Philippe Bressollier; Rachel N Dillard; Daniel L Worthley; Timothy C Wang; Don W Powell; Maria C Urdaci; Irina V Pinchuk
Journal:  Cell Microbiol       Date:  2018-07-26       Impact factor: 3.715

2.  Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.

Authors:  Manisha Bajpai; Darren N Seril; James Van Gurp; Xin Geng; Janet Alvarez; Carlos D Minacapelli; Steve Gorin; Koushik K Das; Elizabeth Poplin; Jerry Cheng; Peter S Amenta; Kiron M Das
Journal:  Dig Dis Sci       Date:  2018-11-26       Impact factor: 3.199

Review 3.  Epigenetic modifications induced by Helicobacter pylori infection through a direct microbe-gastric epithelial cells cross-talk.

Authors:  Lorenzo Chiariotti; Tiziana Angrisano; Simona Keller; Ermanno Florio; Ornella Affinito; Pierlorenzo Pallante; Cinzia Perrino; Raffaela Pero; Francesca Lembo
Journal:  Med Microbiol Immunol       Date:  2013-05-29       Impact factor: 3.402

Review 4.  Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.

Authors:  Afaf A El-Malah; Magdy M Gineinah; Pran Kishore Deb; Ahdab N Khayyat; Monika Bansal; Katharigatta N Venugopala; Anfal S Aljahdali
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-03

5.  Development of Colorectal-Targeted Dietary Supplement Tablets Containing Natural Purple Rice Bran Oil as a Colorectal Chemopreventive.

Authors:  Busaban Sirithunyalug; Chalermpong Saenjum; Suporn Charumanee; Bhagavathi Sundaram Sivamaruthi; Chaiyavat Chaiyasut; Jakkapan Sirithunyalug; Pratchaya Tipduangta
Journal:  Nutrients       Date:  2018-04-04       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.